Venetoclax effects and side effects

Venetoclax is a targeted drug used to treat certain hematological malignancies, mainly chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and acute myeloid leukemia (AML). It works by selectively inhibiting the BCL-2 (BCL-2) protein. BCL-2 is an anti-apoptotic protein that is highly expressed in cancer cells and helps cancer cells resist the natural death mechanism. By inhibiting BCL-2, venetoclax can promote cancer cells to undergo apoptosis and inhibit tumor growth and spread.

1.Treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)

Venetoclax is commonly used to treat patients with CLL and SLL who have become resistant to or have relapsed from other therapies, especially those with 17p chromosomal deletions or TP53 mutations. The cancer cells in these patients are often more resistant to drugs, making venetoclax a very effective treatment option through its specific targeting.

2.Treatment of acute myeloid leukemia (AML)

Venetoclax also shows good efficacy in elderly or frail AML patients who cannot tolerate traditional chemotherapy. Venetoclax is usually used in combination with drugs such as azacitidine or decitabine to improve its efficacy and help patients reduce the number of cancer cells and control their disease.

Side effects of venetoclax

Although venetoclax is effective in treating blood cancers, it can also cause a range of side effects. Most side effects can be managed with monitoring and symptomatic treatment, but some serious side effects require immediate attention.

Common side effects

1.Neutropenia: Neutropenia is one of the most common side effects of venetoclax. Neutrophils are an important type of white blood cell involved in the immune response against infection. Venetoclax may cause a significant decrease in neutrophil counts, thereby increasing the patient's risk of infection. This situation requires regular monitoring of the blood and, if necessary, the use of growth factors or adjustments to the treatment regimen.

2.Anemia and thrombocytopenia: Because venetoclax may affect the normal function of the bone marrow, some patients may experience anemia and thrombocytopenia. This may cause symptoms such as fatigue, dizziness, and easy bleeding or bruising. Severe cases may require blood transfusions or medication dose adjustments.

3.Nausea and vomiting: Some patients experience nausea or vomiting while taking venetoclax, which can be relieved by using antiemetics. To reduce discomfort, patients are advised to take this medication with food.

Severe side effects

1.Tumor lysis syndrome (TLS): This is a more serious side effect caused by venetoclax, which usually occurs in the early stages of treatment. TLSIt is a metabolic disorder caused by the rapid death of cancer cells and the entry of the contents into the blood, which may cause serious complications such as kidney failure and heart problems. To reduce the risk of TLS, doctors often gradually increase the dose of venetoclax at the beginning of treatment and ask patients to stay well hydrated while monitoring electrolyte levels in the blood.

2.Increased risk of infection: Due to venetoclax's suppressive effects on the immune system, patients may be more susceptible to infections, including pneumonia, sepsis, and other bacterial, viral, or fungal infections. During treatment, patients should maintain good hygiene, monitor their body temperature regularly, and seek medical attention immediately if signs of infection appear.

Other side effects

1.Fatigue: Venetoclax may cause severe fatigue and weakness, which may affect patients' daily activities. Patients need to arrange appropriate rest and activities according to their own conditions to maintain quality of life.

2.Gastrointestinal symptoms: In addition to nausea and vomiting, venetoclax may cause diarrhea or constipation. These symptoms are usually mild and can be relieved through diet or medication.

Venetoclax, a targeted anti-cancer drug, has shown significant efficacy in the treatment of specific types of blood cancers. By selectively inhibiting BCL-2 protein, it can effectively induce apoptosis in cancer cells. However, the use of venetoclax is also associated with certain side effects, especially neutropenia, increased risk of infection, and tumor lysis syndrome. Patients should regularly monitor their physical condition during use and conduct treatment under the guidance of a doctor to ensure the safety and effectiveness of the drug.